MicroRNA-92a as a marker of treatment response and survival in adult acute myeloid leukemia patients.

Leukemia & Lymphoma
Reham A RashedMarwa M Hussein

Abstract

This prospective study assessed circulating miR-92a levels in acute myeloid leukemia (AML) at diagnosis and after induction therapy and followed patients for a maximum of 30 months. The study included 63 consecutive adult AML patients. Circulating miR-92a levels were assessed using real-time polymerase chain reaction (RT-PCR). There was significant rise of miR-92a expression after induction (median (range): 0.297 (0.001-3.438)) in comparison to the reported levels at diagnosis (median (range): 0.236 (0.001-3.305)). Post-induction levels of miR-92a are significantly higher in patients who achieved CR in comparison to patients without CR (median (range): 0.408 (0.017-3.438) vs. 0.01 (0.001-1.010), p<.001). Cox hazard regression analysis identified miR-92a as a significant predictor of OS and DFS in univariate and multivariate analyses. In conclusion, baseline circulating miR-92a in AML patients may be a useful prognostic marker of treatment response and survival over 2.5 years follow up.

References

Apr 30, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Guang-Hui LiuXiao-Feng Sun
Mar 15, 2014·Advanced Biomedical Research·Mohammadreza SharifiMohammad Kazemi
Jan 23, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Chuanli RenMing Shen
Jan 21, 2017·Cancer Biomarkers : Section a of Disease Markers·Yalan YuJiancheng Tu
Jun 16, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ofrat Beyar-Katz, Saar Gill
Aug 24, 2018·F1000Research·Justin Watts, Stephen Nimer
Sep 7, 2018·Leukemia & Lymphoma·Chengcheng HeXiaoli Zheng
Nov 15, 2018·Cancers·Mario LuppiAdriano Venditti
Dec 6, 2018·Journal of Cellular Physiology·Rajab MardaniHossein Pourghadamyari
Jun 30, 2019·FEBS Letters·Mariarosaria ConteLucia Altucci
Aug 6, 2019·Frontiers in Genetics·Mengying CuiXuewen Zhang
Aug 7, 2019·Seminars in Cancer Biology·Francesca OrsoDaniela Taverna
Dec 25, 2019·Asian Pacific Journal of Cancer Prevention : APJCP·Marwa M GadoAhmed Osman
Jan 8, 2020·Journal of Blood Medicine·Safaa Aa KhaledDalia G Mahran

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.